Curacle Co

Curacle Co EPS

The Earnings per Share (EPS) of Curacle Co (365270.KQ) as of Oct 19, 2026 is -862.14 KRW. In the previous year, Earnings per Share (EPS) was -912.17 KRW — a change of -5.48% (higher).

EPS

-862.14KRW

YoY

-5.48%

Last updated:

Earnings per Share (EPS) of Curacle Co is 2025 -862.14 KRW. Earnings per Share (EPS) of Curacle Co was 2024 -912.17 KRW. It decreases by -5.48% higher compared to the previous year.

The Curacle Co EPS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EPS
Date
EPS
Jan 1, 2018
-211.68 KRW
Jan 1, 2019
-1,047.41 KRW
Jan 1, 2020
-1,878.11 KRW
Jan 1, 2021
-427.75 KRW
Jan 1, 2022
-823.75 KRW
Jan 1, 2023
-710.87 KRW
Jan 1, 2024
-912.17 KRW
Jan 1, 2025
-862.14 KRW
The Curacle Co EPS history
YEAREPSYoY
-862.14KRW-5.48%
-912.17KRW+28.32%
-710.87KRW-13.70%
-823.75KRW+92.58%
-427.75KRW-77.22%
-1,878.11KRW+79.31%
-1,047.41KRW+394.81%
-211.68KRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Curacle Co Stock analysis

What does Curacle Co do? Curacle Co Ltd is a biotechnology company based in Seoul, South Korea, operating within the healthcare sector. The company focuses on research and experimental development in medical sciences and pharmacy, with a specific emphasis on developing treatments for intractable vascular diseases. As of the latest available information, Curacle employs 35 full-time staff members. The company completed its initial public offering (IPO) on July 22, 2021. Curacle is developing synthetic drugs including CU06-RE, CU01, and a natural drug referred to as CU03, which are targeted at conditions such as diabetic macular edema (DME), diabetic nephropathy (DN), and wet age-related macular degeneration (wet AMD). The company utilizes a platform technology known as SOLVADYS, designed for the development of vascular endothelial dysfunction blockers. Curacle's website is http://www.curacle.com, providing further details about its research and development activities. The company's operations are centered around innovative drug development aimed at addressing significant unmet medical needs in vascular disease treatment. No additional details about founding year, specific executives, or financial figures beyond the IPO date are provided in the available information. Curacle Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Curacle Co stock

Earnings per Share (EPS) of Curacle Co is -862.14 KRW in 2025.

Earnings per Share (EPS) of Curacle Co changed from -912.17 KRW to -862.14 KRW, representing a -5.48% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Earnings per Share (EPS) Curacle Co since 2006 – with annual values, charts, and detailed analysis.

Earnings per Share measures the portion of a company's profit allocated to each outstanding share. It is a key metric for assessing a company's profitability on a per-share basis.

EPS = Net Income / Shares Outstanding

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Curacle Co

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Curacle Co